[go: up one dir, main page]

MX2017003941A - Composicion acuosa. - Google Patents

Composicion acuosa.

Info

Publication number
MX2017003941A
MX2017003941A MX2017003941A MX2017003941A MX2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A MX 2017003941 A MX2017003941 A MX 2017003941A
Authority
MX
Mexico
Prior art keywords
aqueous composition
aquous
composition
aquous composition
formula
Prior art date
Application number
MX2017003941A
Other languages
English (en)
Other versions
MX377963B (es
Inventor
Sugimoto Shin
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2017003941A publication Critical patent/MX2017003941A/es
Publication of MX377963B publication Critical patent/MX377963B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee una composición acuosa que tiene un excelente efecto antiséptico; una composición acuosa que comprende un compuesto representado por la Fórmula (1), en donde X representa un átomo de halógeno, o una sal del mismo, o un solvato del compuesto o la sal del mismo, y un agente tensoactivo de amonio cuaternario. (ver Fórmula).
MX2017003941A 2014-09-25 2015-09-25 Composición acuosa. MX377963B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014194679 2014-09-25
PCT/JP2015/077013 WO2016047719A1 (ja) 2014-09-25 2015-09-25 水性組成物

Publications (2)

Publication Number Publication Date
MX2017003941A true MX2017003941A (es) 2017-06-26
MX377963B MX377963B (es) 2025-03-10

Family

ID=55581238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003941A MX377963B (es) 2014-09-25 2015-09-25 Composición acuosa.

Country Status (17)

Country Link
US (1) US10376523B2 (es)
EP (1) EP3199160B1 (es)
JP (6) JP6236166B2 (es)
KR (1) KR101830588B1 (es)
CN (1) CN106714806B (es)
BR (1) BR112017006150A2 (es)
CA (1) CA2962562A1 (es)
DK (1) DK3199160T3 (es)
ES (1) ES2779314T3 (es)
HU (1) HUE048790T2 (es)
MX (1) MX377963B (es)
MY (1) MY177032A (es)
PL (1) PL3199160T3 (es)
PT (1) PT3199160T (es)
SG (1) SG11201702202UA (es)
TW (1) TWI668215B (es)
WO (1) WO2016047719A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702298VA (en) * 2014-09-25 2017-04-27 Kowa Co Pharmaceutical preparation
WO2022159533A1 (en) * 2021-01-21 2022-07-28 Kowa Company, Ltd. Methods of treating fuchs endothelial corneal dystrophy after descemetorhexis
CN113262226B (zh) * 2021-04-19 2023-05-16 杭州市第一人民医院 利舒地尔在制备细菌感染治疗药物中的应用
WO2025128507A1 (en) * 2023-12-12 2025-06-19 University Of Georgia Research Foundation, Inc. Nitric oxide releasing sponges and methods for making and using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
JPWO2005108446A1 (ja) 2004-05-07 2008-03-21 旭硝子株式会社 含フッ素共重合体とその製造方法およびそれを含むレジスト組成物
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US20060142270A1 (en) 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
JP2006348028A (ja) * 2005-05-19 2006-12-28 Kowa Co 緑内障予防又は治療剤
EP1902731B1 (en) * 2005-06-21 2013-04-10 Kowa Company, Ltd. Preventive or remedy for glaucoma
PL1905452T3 (pl) * 2005-07-12 2013-11-29 Kowa Co Środek do zapobiegania lub leczenia jaskry
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
CA2878370C (en) 2012-07-13 2021-01-19 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
EP3626245B1 (en) 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutic agent for eyeground disease

Also Published As

Publication number Publication date
CN106714806A (zh) 2017-05-24
US20170290841A1 (en) 2017-10-12
JP2024111298A (ja) 2024-08-16
JP2021143179A (ja) 2021-09-24
DK3199160T3 (da) 2020-04-20
JP2018012736A (ja) 2018-01-25
PL3199160T3 (pl) 2020-07-27
WO2016047719A1 (ja) 2016-03-31
KR101830588B1 (ko) 2018-02-20
JP2023052791A (ja) 2023-04-12
MY177032A (en) 2020-09-02
CN106714806B (zh) 2020-03-03
EP3199160A4 (en) 2018-04-25
PT3199160T (pt) 2020-04-08
EP3199160A1 (en) 2017-08-02
KR20170063565A (ko) 2017-06-08
US10376523B2 (en) 2019-08-13
ES2779314T3 (es) 2020-08-14
JPWO2016047719A1 (ja) 2017-06-29
SG11201702202UA (en) 2017-04-27
TWI668215B (zh) 2019-08-11
EP3199160B1 (en) 2020-03-11
BR112017006150A2 (pt) 2017-12-12
JP2019194273A (ja) 2019-11-07
HUE048790T2 (hu) 2020-09-28
MX377963B (es) 2025-03-10
CA2962562A1 (en) 2016-03-31
TW201619147A (zh) 2016-06-01
JP6236166B2 (ja) 2017-11-22

Similar Documents

Publication Publication Date Title
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
GEAP202215378A (en) Microbiocidal thiazole derivatives
BR112017006253A2 (pt) novos compostos
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
MX387483B (es) Preparación farmacéutica.
MX391539B (es) Proceso de compuesto antifungico.
EA201891409A1 (ru) Бензамидные соединения и их применение в качестве гербицидов
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201990833A1 (ru) Соединение пиридина
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
MX2019007571A (es) Polimorfos.
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MY178881A (en) Novel aqueous composition
MX387796B (es) Compuestos de aminocarbonilcarbamato.
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
MY178880A (en) Composition
MX2016015856A (es) Derivados de naftiridinadiona.
MX2020006016A (es) Polimorfos.
MX2017003941A (es) Composicion acuosa.
JOP20200030A1 (ar) مركب خماسي الحلقة
MY178370A (en) Aqueous composition